title: Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.
abstract: Synaptic dopamine release from embryonic nigral transplants has been monitored in the striatum of a patient with Parkinson's disease using [11C]-raclopride positron emission tomography to measure dopamine D2 receptor occupancy by the endogenous transmitter. In this patient, who had received a transplant in the right putamen 10 years earlier, grafts had restored both basal and drug-induced dopamine release to normal levels. This was associated with sustained, marked clinical benefit and normalized levels of dopamine storage in the grafted putamen. Despite an ongoing disease process, grafted neurons can thus continue for a decade to store and release dopamine and give rise to substantial symptomatic relief.
authors.affiliation: MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. paola@cu.rpms.ac.uk
authors.forename: P
authors.initials: P
authors.lastname: Piccini
authors.forename: D J
authors.initials: DJ
authors.lastname: Brooks
authors.forename: A
authors.initials: A
authors.lastname: Björklund
authors.forename: R N
authors.initials: RN
authors.lastname: Gunn
authors.forename: P M
authors.initials: PM
authors.lastname: Grasby
authors.forename: O
authors.initials: O
authors.lastname: Rimoldi
authors.forename: P
authors.initials: P
authors.lastname: Brundin
authors.forename: P
authors.initials: P
authors.lastname: Hagell
authors.forename: S
authors.initials: S
authors.lastname: Rehncrona
authors.forename: H
authors.initials: H
authors.lastname: Widner
authors.forename: O
authors.initials: O
authors.lastname: Lindvall
mesh_terms: D000368:Aged; D001665:Binding Sites / Q000187:drug effects; D016380:Brain Tissue Transplantation; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D016332:Fetal Tissue Transplantation; D006085:Graft Survival; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D008875:Middle Aged; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000637:transplantation*; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology / Q000601:surgery*; D011699:Putamen / Q000187:drug effects / Q000378:metabolism; D020891:Raclopride / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D013378:Substantia Nigra / Q000166:cytology / Q000196:embryology / Q000637:transplantation; D013569:Synapses / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
chemical_list: D017448:Receptors, Dopamine D2; D020891:Raclopride; D008694:Methamphetamine; D004298:Dopamine